Cargando…
14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer
About one-fourth of recurrent estrogen receptor–positive (ER+) breast cancers lose ER expression, leading to endocrine therapy failure. However, the mechanisms underlying ER loss remain to be fully explored. We now show that 14-3-3τ, up-regulated in ∼60% of breast cancer, drives the conversion of ER...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618134/ https://www.ncbi.nlm.nih.gov/pubmed/36252018 http://dx.doi.org/10.1073/pnas.2209211119 |